Addressing IOP and QOL With LAL, iStent, and Dextenza

Show Description +

I. Paul Singh, MD, discusses the current technologies available to maintain good quality of life (QOL) for patients while also aggressively managing IOP. In this case, the patient had a history of primary open-angle glaucoma and monovision. Dr. Singh demonstrates the implantation of an Light Adjustable Lens (LAL, RxSight) and iStent (Glaukos) with use of Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix).

Posted: 2/27/2023

Addressing IOP and QOL With LAL, iStent, and Dextenza

I. Paul Singh, MD, discusses the current technologies available to maintain good quality of life (QOL) for patients while also aggressively managing IOP. In this case, the patient had a history of primary open-angle glaucoma and monovision. Dr. Singh demonstrates the implantation of an Light Adjustable Lens (LAL, RxSight) and iStent (Glaukos) with use of Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix).

Posted: 2/27/2023

Please log in to leave a comment.

More in Cataract

Phacoemulsification With Real-Time Remote Collaboration

Ernesto Calvo, MD; Salomon Abouganem, MD; and Eric Rosenberg, DO

Case-Based Confidence With LenSx® OnAxis

Zarmeena Vendal, MD; Scott LaBorwit, MD; and Heather Weissman, MD

OnAxis Workflow Confidence From Clinic to OR

Zarmeena Vendal, MD; Scott LaBorwit, MD; and Heather Weissman, MD

LenSx® Momentum and the Platform That Keeps Evolving

Zarmeena Vendal, MD; Scott LaBorwit, MD; and Heather Weissman, MD